Clinical trial
A Phase 1, Open-label, Parallel Group Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Relapsed/Refractory Hematologic Malignancies and Severe Hepatic or Renal Impairment or Normal Hepatic and Renal Function
NCT07923071 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, Parallel Group Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Relapsed/Refractory Hematologic Malignancies and Severe Hepatic or Renal Impairment or Normal Hepatic and Renal Function
- Lead sponsor
- Syndax Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- January 31, 2032
- Enrollment
- 18 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
acute leukemia, refractory leukemia, relapsed leukemia, relapsed/refractory (r/r) hematologic malignancies
Arms
As registered; 3 arms.
-
Group A: Severe Hepatic Impairment
PK evaluation Period: Participants will receive a single Reduced Dose A of revumenib on Day 1.
Optional Treatment Period: If the Investigator believes it is in the best clinical interest of the participant, the participant may start the Optional Treatment Period immediately after completing the PK Evaluation Period on Study Day 2.
Participants who start the Optional Treatment Period will receive revumenib twice daily (Q12h), which may be continued for up to 2 years.
-
Group B: Severe Renal Impairment
PK evaluation Period: Participants will receive a single Reduced Dose B of revumenib on Day 1.
Optional Treatment Period: If the Investigator believes it is in the best clinical interest of the participant, the participant may start the Optional Treatment Period immediately after completing the PK Evaluation Period on Study Day 2.
Participants who start the Optional Treatment Period will receive revumenib twice daily, which may be continued for up to 2 years.
-
Group C: Normal Hepatic and Renal Function
PK evaluation Period: Participants will receive a single Recommended Dose of revumenib on Day 1.
Optional Treatment Period: If the Investigator believes it is in the best clinical interest of the participant, the participant may start the Optional Treatment Period immediately after completing the PK Evaluation Period on Study Day 2.
Participants who start the Optional Treatment Period will receive revumenib twice daily, which may be continued for up to 2 years.
Primary endpoints
Registered primary outcome measures; 6 primary.
-
Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of Revumenib
-
Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of M1
-
Maximum Observed Concentration (Cmax) of Revumenib
-
Maximum Observed Concentration (Cmax) of M1
-
Terminal Elimination Half-Life (t1/2) of Revumenib
+1 more primary endpoint
Lead sponsor's other trials
Syndax Pharmaceuticals, most recent start first.
+25 more trials See the organization page
Similar trials
Same condition (Leukemia, Biphenotypic, Acute) and phase, most recent start first.
+63 more trials See the condition page